Ignite Creation Date:
2025-12-25 @ 5:05 AM
Ignite Modification Date:
2026-03-04 @ 7:06 PM
Study NCT ID:
NCT00044018
Status:
COMPLETED
Last Update Posted:
2019-11-12
First Post:
2002-08-16
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
CDC-501 Therapy in Relapsed or Refractory Multiple Myeloma
Sponsor:
Celgene
Organization:
Study Overview
Official Title:
An Open-Label Study to Evaluate the Efficacy and Safety of Two CDC-501 Dose Regimens When Used Alone or in Combination With Dexamethasone for the Treatment Relapsed or Refractory Multiple Myeloma
Status:
COMPLETED
Status Verified Date:
2019-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the study is to select the dose regimen of CDC-501 that provides the most promising evidence of efficacy.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: